Stockscreener 앱 받기
13.95
10.86%
-1.70
전일 마감가:
$15.65
열려 있는:
$15.57
하루 거래량:
3.35M
Relative Volume:
1.83
시가총액:
$721.18M
수익:
$170.44M
순이익/손실:
$-193.88M
주가수익비율:
-3.7159
EPS:
-3.7541
순현금흐름:
$-126.38M
1주 성능:
+5.05%
1개월 성능:
+127.57%
6개월 성능:
-4.39%
1년 성능:
+53.97%
1일 변동 폭
$13.42
$15.65
1주일 범위
$13.42
$15.88
52주 변동 폭
$5.455
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
13.95 | 721.18M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-07 | 재개 | Raymond James | Outperform |
| 2024-11-15 | 재개 | Morgan Stanley | Overweight |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-06-07 | 개시 | Goldman | Buy |
| 2024-03-11 | 개시 | H.C. Wainwright | Buy |
| 2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 재개 | Raymond James | Outperform |
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
RegenxBio doses first patient in phase 2b/3 trial for DR - Eyes On Eyecare
REGENXBIO Inc. (RGNX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
(RGNX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Regenxbio Inc outlines gene therapy pipeline as Nasdaq-listed biotech stays focused on long-term gro - ad-hoc-news.de
First Patient Dosed in Phase 2b/3 NAAVIGATE Trial of Gene Therapy Surabgene Lomparvovec in Diabetic Retinopathy - CGTLive®
Regenxbio CMO Steve Pakola sells $29,476 in common stock - Investing.com
Regenxbio CMO Steve Pakola sells $29,476 in common stock By Investing.com - Investing.com Australia
Form 4 Regenxbio Inc For: 6 July By Investing.com - Investing.com South Africa
REGENXBIO (RGNX) CEO logs ESPP share acquisitions and tax-withholding stock disposition - Stock Titan
REGENXBIO (RGNX) CMO Pakola exercises options and sells 2,161 shares under plan - Stock Titan
REGENXBIO (RGNX) completes employee option exchange, grants 775,401 replacement options - Stock Titan
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
REGENXBIO Inc updates pipeline strategy as gene therapy sector evolves - AD HOC NEWS
Regenxbio Insider Sold Shares Worth $688,756, According to a Recent SEC Filing - marketscreener.com
Form 4 Regenxbio Inc For: 1 July By Investing.com - Investing.com Canada
Regenxbio CMO Steve Pakola sells $688,755 in company stock. By Investing.com - Investing.com Nigeria
[Form 4] REGENXBIO Inc. Insider Trading Activity - Stock Titan
Regenxbio CMO Steve Pakola sells $688,755 in company stock. - Investing.com
Regenxbio Chief Medical Officer Sold Shares Worth Over $688K - TradingView
Proposed 43,206-share sale for RGNX (NASDAQ: RGNX) tied to option exercise - Stock Titan
H.C. Wainwright reiterates Regenxbio stock rating on trial milestone By Investing.com - Investing.com South Africa
REGENXBIO (RGNX) amends Schedule TO to update employee option exchange content - Stock Titan
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $26 - Moomoo
H.C. Wainwright reiterates Regenxbio stock rating on trial milestone - Investing.com
REGENXBIO Inc.(NasdaqGS: RGNX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
REGENXBIO Inc.(NasdaqGS: RGNX) added to Russell 2500 Growth Benchmark - marketscreener.com
REGENXBIO doses first patient in DR trial - grafa.com
Regenxbio doses first patient in diabetic retinopathy trial By Investing.com - Investing.com Nigeria
Regenxbio doses first patient in diabetic retinopathy trial - Investing.com
Regenxbio Advances Diabetic Retinopathy Gene Therapy Trial - TipRanks
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone - The AI Journal
REGENXBIO doses first patient in Phase IIb/III trial for diabetic retinopathy therapy - Traders Union
$100M AbbVie payment backs REGENXBIO (RGNX) Phase IIb/III eye gene therapy - Stock Titan
REGENXBIO doses first patient in eye-disease gene therapy trial - Stock Titan
REGENXBIO Inc.(NasdaqGS: RGNX) added to Russell 2000 Growth Benchmark - marketscreener.com
REGENXBIO Inc.(NasdaqGS: RGNX) added to Russell 3000E Growth Benchmark - marketscreener.com
Regenxbio shares rise on plans to resubmit Navsunli BLA for MPS II - MSN
REGENXBIO Inc.(NasdaqGS: RGNX) added to Russell 3000 Growth Benchmark - marketscreener.com
Liquidity Mapping Around (RGNX) Price Events - Stock Traders Daily
Regenxbio: 'Strong Buy' On FDA Course Reversal For NAVSUNLI And Potential AA DMD Filing - Seeking Alpha
Enterprise value to EBITDA forward of REGENXBIO Inc. – NASDAQ:RGNX - TradingView
Enterprise value to revenue forward of REGENXBIO Inc. – NASDAQ:RGNX - TradingView
Enterprise value to revenue forward of REGENXBIO, Inc. – MUN:RB0 - TradingView
Enterprise value to EBITDA forward of REGENXBIO, Inc. – MUN:RB0 - TradingView
Enterprise value to EBIT forward of REGENXBIO, Inc. – MUN:RB0 - TradingView
Price to sales forward of REGENXBIO Inc. – NASDAQ:RGNX - TradingView
Price to book forward of REGENXBIO Inc. – NASDAQ:RGNX - TradingView
Price to book forward of REGENXBIO, Inc. – MUN:RB0 - TradingView
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Regenxbio Inc 주식 (RGNX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| PAKOLA STEVE | Chief Medical Officer |
Jul 02 '26 |
Sale |
13.64 |
2,161 |
29,476 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Option Exercise |
7.86 |
36,725 |
288,658 |
249,734 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Sale |
12.86 |
36,725 |
472,284 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jun 29 '26 |
Sale |
11.04 |
19,608 |
216,472 |
213,009 |
2.64%
자본화:
|
볼륨(24시간):